MAOBI use in PD rose to prominence at the turn of the millennium, with selegiline postulated to have a possible neuroprotective effect based on its capacity to inhibit MAO-B oxidation of MPTP to MPP + which is toxic to dopaminergic neurons [16]. This evidence concerns the gene MAOB and Parkinson disease.